If you have been reading about freeze-thaw cycle and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-26. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Smaller-scale art flourished throughout the entire Byzantine period: costly ivory carvings—often as diptychs (Barberini ivory) or triptychs (Harbaville Triptych)—featured imperial commemorations or religious scenes and were particularly valued, as were metalwork and enamels. Other costly objects included illuminated manuscripts, which were lavishly illustrated for a wide range of texts, and silks, often dyed in the prized imperial purple; both became highly popular in Western Europe. The rise of small, portable icon paintings, used for both public and private religious worship, grew increasingly controversial. During two periods of Byzantine Iconoclasm (726–843), possibly influenced by Islamic prohibitions on religious images, icons were suppressed and enormous amounts of figurative religious art was destroyed. Iconoclasts condemned their use, likening them to pagan idolatry and ascribing recent Umayyad defeats as divine retribution for their use. Iconophiles eventually prevailed, maintaining their essential use for veneration, considered distinct from worship, and found precedent in gospel references. Post-iconoclast Macedonian art (867–1056) saw a cultural renaissance, and many artworks from this period survive. Subjects and styles became standardised, particularly cross-in-square churches, and already-existing frontality and symmetry evolved into a dominant artistic aesthetic, observable in the small Pala d'Oro enamel and the large mosaics of the Hosios Loukas, Daphni, and Nea Moni monasteries.
== Localization == As a GPI-anchored protein, Thy-1 is present in the outer leaflet of lipid rafts in the cell membrane. In case of neurons it is known to be expressed strongly in the mature axon. The axon hillock can act as a barrier for its lateral spread even though it has no transmembrane segment. Thy-1 has been suggested to interact with G inhibitory proteins, the Src family kinase (SFK) member c-fyn, and tubulin within lipid rafts. In rats and mice, Thy-1 protein is present on the soma (cell body) and dendrites of neurons but is not expressed on axons until axonal growth is complete, and is again temporarily suppressed during axonal injury. HIV-1 Matrix co-localizes with Thy-1 in lipid rafts, the site of virus particle budding from cells, and Thy-1 is incorporated into virus particles as a result of this process.
LSD's psychedelic properties were discovered 5 years later when Hofmann himself accidentally ingested an unknown quantity of the chemical. The first intentional ingestion of LSD occurred on April 19, 1943, when Hofmann ingested 250 μg of LSD. He said this would be a threshold dose based on the doses of other ergot alkaloids; however, Hofmann found the effects to be much stronger than he anticipated. Information about synthesizing LSD was first published in scientific literature by Hofmann and his colleague, psychiatrist Werner Stoll in 1943; a description of LSD's hallucinogenic effects was later published by Stoll in 1947.
== Research / Education == At least three universities offer graduate degrees dedicated to molecular engineering: the University of Chicago, the University of Washington, and Kyoto University. These programs are interdisciplinary institutes with faculty from several research areas. The academic journal Molecular Systems Design & Engineering publishes research from a wide variety of subject areas that demonstrates "a molecular design or optimisation strategy targeting specific systems functionality and performance."
Sources: en.wikipedia.org
Alkaline phosphatase: Secreted by osteoblasts during active bone formation; elevated levels indicate increased osteoid production Osteocalcin: A bone-specific protein synthesized by osteoblasts and incorporated into osteoid; serves as a marker of bone formation Type I collagen peptides: Degradation products measured to assess bone turnover
== History == The history of today's Gelita AG in Eberbach dates back to 1875, when the production of gelatin was started in Schweinfurt. Gelita was preceded by the founding of the "Gebrüder Köpff Company", Heinrich Koepff's small tannery, in 1883. Shaken by the economic crisis of the time, Heinrich saw a way out of his misery in gelatin production. The raw material for this could be purchased cheaply, as it was produced in the large tanneries as residual material. With around 60 employees, the factory was already producing photographic gelatin in 1884, which was an important material for the rapidly emerging photography in the 19th century. In 1887, the Koepff brothers acquired the competing company A. & C. Wolff in Heilbronn. Both locations had 320 employees who produced 400 tonnes of gelatin per year. In 1901, a major fire destroyed large parts of the factory. The brothers quarreled over reconstruction. Heinrich went to Heilbronn and Paul Koepff continued to run the rebuilt plant alone under the name Göppinger Gelatin Factory Paul Koepff. In 1911, he sold the factory to DGF AG, which already operated gelatin factories in Schweinfurt and Höchst. Paul Koepff was henceforth on the board of directors and continued to manage his former company as director. In 1929, Paul Koepff jr. took over the management of the Göppingen plant from his father, who died in 1953. The Gelita Brand was introduced in 1934. In 1937, the DGF was accused of violating foreign trade regulations and leading employees were arrested.
=== Achondrogenesis type 2 === Several kinds of mutations in the COL2A1 gene are responsible for achondrogenesis type 2. These include missing pieces of the gene, substitution of the amino acid glycine with another amino acid, or changes that result in truncated proteins. All these mutations disrupt the production of mature type II collagen, affecting tissues rich in this collagen.
== Interactions == Methocarbamol may inhibit the effects of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in those with myasthenia gravis taking anticholinesterase medications. Methocarbamol may disrupt certain screening tests as it can cause color interference in laboratory tests for 5-hydroxy-indoleacetic acid (5-HIAA) and in urinary testing for vanillylmandelic acid (VMA) using the Gitlow method.
There were no reports of cross-border operations from either of the ethnic militant groups, although Iran had engaged in attacks against both of them, reportedly killing both Kurdish fighters of the Coalition of Political Forces of Iranian Kurdistan and Baloch fighters of the People's Fighters Front originating from outside Iran. Analysis of satellite images by The Washington Post revealed damage to at least 228 structures or pieces of equipment at US bases across the Persian Gulf, far more than the Trump administration has admitted to. On 1 March, six US soldiers were killed amid more than 30 injured in an Iranian drone attack near Camp Arifjan in Port Shuaiba, Kuwait. Those killed were soldiers of the United States Army Reserve assigned to the 103rd Expeditionary Sustainment Command, headquartered in Des Moines, Iowa. On 8 March, CENTCOM reported that a National Guard soldier died during a medical emergency. A soldier of the 1st Space Brigade was wounded in an attack against Prince Sultan Air Base on 1 March and died from his injuries on 9 March. According to a May report by the Congressional Research Service, 42 U.S. military aircraft were destroyed or damaged during the Iran-U.S. conflict. Data from the Center for Strategic and International Studies (CSIS) indicates that about 65 percent of the 2,330 US Patriot interceptor missiles available at the beginning of the conflict with Iran were used between February and July, leaving less than 850 missiles remaining.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.